• Human APIs PowderRespiratory Drugs Raw Material Antiviral Antibacterial Antipyretic Analgesics Antihistamine Drugs Antineoplastic Cosmetic Raw Material
  • Pharmaceutical IntermediatesPharmaceutical intermediates Nutritional Supplements Pharmaceutical raw materials
  • OEM & ODMCapsule Softgel Capsule Gummies Drop & drinks Tables
  • Veterinary raw materialsAntibacterial anti-inflammatory Respiratory Drugs Anthelmintics Antiviral drugs Feed additives
  • About UsCompany profileQualificationQuality AssuranceService teamFactory TourR&D Center
  • Raw material intermediate Danofloxacin mesylate Powder

    • Raw material intermediate Danofloxacin mesylate Powder
    • Raw material intermediate Danofloxacin mesylate Powder storehouse
    • Raw material intermediate Danofloxacin mesylate Powder quality testing
    • Raw material intermediate Danofloxacin mesylate Powder quality testing
    • Raw material intermediate Danofloxacin mesylate Powder certificate

    Product Overview:

    Darifloxacin mesylate has strong antibacterial effects mainly against Gram-positive bacteria (G+), certain anaerobes and mycoplasmas. It is sensitive to Streptococcus aureus, Streptococcus haemolyticus, Pneumococcus, Legionella pneumophila, Mycoplasma, and also sensitive to Clostridium difficile, Clostridium weissei, Tetanus bacillus, and Mycobacterium avium.

    Raw material intermediate Danofloxacin mesylate Powder Attributes

    Raw material intermediate Danofloxacin mesylate Raw Materials Powder

    CAS:119478-55-6

    MF:C20H24FN3O6S

    Danofloxacin mesylate

    MW:453.48

    EINECS:638-813-3

    Specification​: 99% min Danofloxacin mesylate Powder

    Sample: Danofloxacin mesylate Powder

    Packaging:1kg/bag, 25kg/drum

    Brand: Henrikang

    Appearance: White to Off-White

    Storage: Cool Dry Place

    Shelf Life: 2 Years

    Test Method: HPLC

    Raw material intermediate Danofloxacin mesylate Powder Details

    Danofloxacin mesylate Powder Usage and Synthesis.

    Darifloxacin mesylate has strong antibacterial effects mainly against Gram-positive bacteria (G+), certain anaerobes and mycoplasmas. It is sensitive to Streptococcus aureus, Streptococcus haemolyticus, Pneumococcus, Legionella pneumophila, Mycoplasma, and also sensitive to Clostridium difficile, Clostridium weissei, Tetanus bacillus, and Mycobacterium avium.

    Danofloxacin mesylate Powder

    Uses of Danofloxacin mesylate.

    For infections of livestock (G+) bacteria, certain anaerobes, mycoplasma and spirochetes.

    1. lung infections caused by a mixture of Staphylococcus aureus, Streptococcus haemolyticus, Pneumococcus, Legionella pneumophila.

    2. avian chronic respiratory disease caused by Mycoplasma, porcine asthma.

    3. proliferative enteritis, spirochete dysentery, toxoplasmosis in pigs; 4. necrotising enteritis in chickens.

    4. necrotising enteritis in chickens; 5. actinomycosis in pets.

    5. pet actinomycosis.

    Danofloxacin mesylate

    Pharmacological Effects of Danofloxacin mesylate.

    Darifloxacin mesylate has strong antibacterial effects mainly against Gram-positive bacteria (G+), certain anaerobes and mycoplasmas. It is sensitive to Streptococcus aureus, Streptococcus haemolyticus, Pneumococcus, Legionella pneumophila, Mycoplasma, and also sensitive to Clostridium difficile, Clostridium weissei, Tetanus bacillus, and Mycobacterium avium.

    Dafloxacin mesylate is clinically used for infections caused by epimycin-resistant and erythromycin-resistant bacteria; mycoplasma infections caused by avian chronic respiratory disease and porcine asthma; necrotising enteritis in chickens; porcine dense spirochete dysentery, toxoplasmosis; pet actinomycosis.

    API Danofloxacin mesylate Raw

    In vitro studies of Danofloxacin mesylate.

    Danofloxacin is a synthetic antimicrobial agent of the fluoroquinolone class that acts primarily through inhibition of bacterial DNA-promoter enzymes, which are necessary for DNA super-helixation to provide proper spatial arrangement of DNA in the bacterial cell.The minimum inhibitory concentration (MIC) of Danofloxacin, resistant to 90 per cent (MIC90) contemporary European and North American regional Pasteurellahaemolytica, Pasteurellamultocida and Haemophilussomnus, the most important respiratory pathogens of livestock, was 0.125 µg/ml

    Our advantage
    Our Factory
    Shipping
    Tel: 86-29-89601602
    WhatsApp: 8615091775531
    WeChat: 15091775531
    E-mail: sales21@interlgroup.com
    Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
    ©2023 Xi'an Henrikang Biotech Co., Ltd.,